MX2021012960A - Composiciones y metodos de uso de cannabinoides para neuroproteccion. - Google Patents
Composiciones y metodos de uso de cannabinoides para neuroproteccion.Info
- Publication number
- MX2021012960A MX2021012960A MX2021012960A MX2021012960A MX2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A
- Authority
- MX
- Mexico
- Prior art keywords
- neuroprotection
- compositions
- methods
- cannabinoids
- neuroprotective composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838216P | 2019-04-24 | 2019-04-24 | |
| PCT/CA2020/050547 WO2020215164A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012960A true MX2021012960A (es) | 2022-01-04 |
Family
ID=72940570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012960A MX2021012960A (es) | 2019-04-24 | 2020-04-24 | Composiciones y metodos de uso de cannabinoides para neuroproteccion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230043428A1 (https=) |
| EP (1) | EP3958856A4 (https=) |
| JP (1) | JP7633179B2 (https=) |
| KR (1) | KR20220080045A (https=) |
| CN (1) | CN114007603A (https=) |
| AU (1) | AU2020261515B2 (https=) |
| CA (1) | CA3134764A1 (https=) |
| IL (1) | IL287536B2 (https=) |
| MX (1) | MX2021012960A (https=) |
| SG (1) | SG11202111809XA (https=) |
| WO (1) | WO2020215164A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115006404A (zh) * | 2022-08-09 | 2022-09-06 | 昆药集团股份有限公司 | 一种具有视神经保护功效的药物组合物及其应用 |
| WO2024091653A1 (en) * | 2022-10-27 | 2024-05-02 | Kemin Industries, Inc. | Use of a spearmint extract for retina neurotrophism |
| WO2024148117A2 (en) * | 2023-01-04 | 2024-07-11 | Florascience Inc. | Methods of treating neurodegenerative diseases or conditions |
| WO2025090133A1 (en) * | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Compositions and methods for use of cannabinol compounds in neuroprotection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| EP2640379A4 (en) * | 2010-11-18 | 2014-08-13 | Pier Pharmaceuticals | LOW DOSED CANNABINOIDARY MEDICINES |
| BR122021018502B1 (pt) * | 2014-10-21 | 2022-05-03 | United Cannabis Corp | Formulação de canabinoide líquida |
| MA41299A (fr) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| CN107405314A (zh) * | 2015-02-27 | 2017-11-28 | 埃布公司 | 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物 |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| US20170266153A1 (en) * | 2015-02-27 | 2017-09-21 | Ebbu, LLC | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| US20160282371A1 (en) * | 2015-03-28 | 2016-09-29 | Quantalytical Labs Inc. | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
| CN109963595B (zh) * | 2016-10-11 | 2023-02-03 | Gbs全球生物制药公司 | 用于治疗神经退行性疾病的含有大麻素的复合混合物 |
| WO2018118197A1 (en) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Healthier aging in domesticated animals |
| WO2018205022A1 (en) * | 2017-05-08 | 2018-11-15 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
| WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
| US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
-
2020
- 2020-04-24 KR KR1020217036628A patent/KR20220080045A/ko not_active Withdrawn
- 2020-04-24 EP EP20794650.0A patent/EP3958856A4/en active Pending
- 2020-04-24 IL IL287536A patent/IL287536B2/en unknown
- 2020-04-24 JP JP2021563360A patent/JP7633179B2/ja active Active
- 2020-04-24 CN CN202080046190.4A patent/CN114007603A/zh active Pending
- 2020-04-24 SG SG11202111809XA patent/SG11202111809XA/en unknown
- 2020-04-24 US US17/606,003 patent/US20230043428A1/en active Pending
- 2020-04-24 CA CA3134764A patent/CA3134764A1/en active Pending
- 2020-04-24 MX MX2021012960A patent/MX2021012960A/es unknown
- 2020-04-24 WO PCT/CA2020/050547 patent/WO2020215164A1/en not_active Ceased
- 2020-04-24 AU AU2020261515A patent/AU2020261515B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL287536A (en) | 2021-12-01 |
| AU2020261515A1 (en) | 2021-11-18 |
| WO2020215164A1 (en) | 2020-10-29 |
| EP3958856A4 (en) | 2023-01-25 |
| IL287536B2 (en) | 2026-03-01 |
| US20230043428A1 (en) | 2023-02-09 |
| SG11202111809XA (en) | 2021-11-29 |
| IL287536B1 (en) | 2025-11-01 |
| JP2022530471A (ja) | 2022-06-29 |
| JP7633179B2 (ja) | 2025-02-19 |
| AU2020261515B2 (en) | 2025-10-23 |
| KR20220080045A (ko) | 2022-06-14 |
| EP3958856A1 (en) | 2022-03-02 |
| CN114007603A (zh) | 2022-02-01 |
| CA3134764A1 (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012960A (es) | Composiciones y metodos de uso de cannabinoides para neuroproteccion. | |
| NI201900062A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP18073264A (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073245A (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| MX2019013878A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| CR20180496A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2018005971A2 (es) | Composición de regulador de crecimiento vegetal que tiene efecto sinérgico | |
| MX2020004678A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| MX2017003788A (es) | Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial. | |
| MX2020012014A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas | |
| UY37555A (es) | Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO2017003848A1 (es) | Composición que comprende extractos de guadua angustifolia para la prevención o el tratamiento de enfermedades de la retina | |
| MX2020009396A (es) | Metodos de uso y composiciones farmaceuticas de un inhibidor selectivo de syk. | |
| AR090580A1 (es) | Composiciones farmaceuticas para terapia combinada |